MARLBOROUGH, Mass.,
Sept. 29, 2015 /PRNewswire/ -- Boston Scientific
Corporation (NYSE: BSX) announced today the launch of the
Captivator™ EMR Device for Endoscopic Mucosal Resection (EMR), a
minimally invasive alternative to an esophagectomy, a surgical
procedure that removes part of the esophagus in upper
gastrointestinal (GI) tract cases. EMR enables staging and removal
of precancerous tissue and early esophageal cancer in the upper GI
tract during an endoscopic outpatient procedure. The Captivator EMR
Device is specifically designed for upper GI EMR and provides
physicians with enhanced visualization, control and easy passage of
devices.
Experience the interactive Multimedia News Release here:
http://www.multivu.com/players/English/7223458-boston-scientific-captivator-emr-device/
A common precursor to esophageal cancer is Barrett's Esophagus,
which is a complication of acid reflux disease that causes
abnormal changes to the lining of the esophagus. More than 900,000
people worldwide are diagnosed with Barrett's Esophagus[1]. Nearly
10 percent of patients with chronic heartburn develop Barrett's
Esophagus and endoscopic management may help reduce the potential
for an esophagectomy, a more invasive and costly
surgery.[2],[3]
The company also enrolled the first patient in a multi-center,
prospective, post-market registry initiated to study the
performance of the Captivator EMR Device for endoscopic resection
of abnormal tissue growth known as early neoplasia, specifically in
Barrett's Esophagus. It will document procedural success,
procedure time, quality of acquired tissue for histopatholgy, and
procedural complications. The registry will enroll approximately
300 patients at 16 clinical centers in eight countries, and is
expected to be completed in 2016.
"The Captivator EMR Device provides improved endoscopic
visualization, so the resection can be better directed to the area
of interest," said Dr. Jacques
Bergman, professor of Gastrointestinal Endoscopy at
University of Amsterdam, the
Netherlands, and lead investigator of the global registry.
"The enhanced view, along with easy passage of accessory devices
and the ability to use compatible hemostatic devices to manage
potential bleeding and complications may enable a safer endoscopic
resection."
The Captivator EMR Device provides physicians with a 360 degree
unobstructed peripheral view for more complete visualization of the
diseased area when performing resections. And unlike other EMR
devices, accessory devices such as the Boston Scientific
Resolution™ Clip and Interject™ Needle can be used with the device
during the procedure to manage potential complications quickly. The
Captivator EMR Device is also currently the only EMR device that
includes a pathology kit to provide added convenience for
endoscopists and pathologists.
"As a leader in GI endoscopic devices, this launch complements
our existing product offering for lower GI EMR procedures, and
expands our portfolio into the growing upper GI EMR segment ," said
David Pierce, senior vice president
and president, Endoscopy, Boston Scientific. "The Captivator EMR
Device provides physicians and patients with an important new
option for staging and treating early esophageal neoplasia and
cancer."
The Captivator EMR Device is available in the United States, Europe, Singapore, Australia and Puerto
Rico.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology leader
for more than 35 years, we advance science for life by providing a
broad range of high performance solutions that address unmet
patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect on Twitter
and Facebook.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of
1934. Forward-looking statements may be identified by words
like "anticipate," "expect," "project," "believe," "plan,"
"estimate," "intend" and similar words. These forward-looking
statements are based on our beliefs, assumptions and estimates
using information available to us at the time and are not intended
to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding new product, markets for our products, product
performance and impact and competitive offerings. If our
underlying assumptions turn out to be incorrect, or if certain
risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in
some cases, have affected and in the future (together with other
factors) could affect our ability to implement our business
strategy and may cause actual results to differ materially from
those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place
undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All of
these factors are difficult or impossible to predict accurately and
many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties
that may affect our future operations, see Part I, Item 1A – Risk
Factors in our most recent Annual Report on Form 10-K filed with
the Securities and Exchange Commission, which we may update in Part
II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we
have filed or will file hereafter. We disclaim any intention or
obligation to publicly update or revise any forward-looking
statements to reflect any change in our expectations or in events,
conditions or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements. This
cautionary statement is applicable to all forward-looking
statements contained in this document.
CONTACTS:
Media: Nisha Deo
408-893-9243 (cell)
Global Media Relations
Boston Scientific Corporation
Nisha.Deo@bsci.com
Investors: Susie Lisa, CFA
508-683-5565 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com
[1]
http://gi.org/guideline/diagnosis-surveillance-and-therapy-of-barrett%E2%80%99s-esophagus/
[2]
http://www.webmd.com/heartburn-gerd/guide/barretts-esophagus-symptoms-causes-and-treatments
[3] Datasource: Medicare's MedPar 2012 and Medicare's OPPS
2012 (Outpatient Prospective Payment System) files
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boston-scientific-launches-the-captivator-emr-device-to-treat-diseases-of-the-upper-gi-tract-300150581.html
SOURCE Boston Scientific Corporation